Pangaea Express - CADTH engages with pCPA

June 20, 2016

CADTH is now involving the pan-Canadian Pharmaceutical Alliance (pCPA) office in the CADTH Common Drug Review (CDR) and pan-Canadian Oncology Drug Review (pCODR) processes.

The purpose of this engagement is to allow the pCPA office to receive relevant drug information in a timely manner. The pCPA will not provide confidential negotiation information to CADTH but will mostly observe, ask questions and receive the drug submission information as per the CDR and pCODR review processes.

The pCPA Office will hold the following specific roles:

CDR and pCODR pre-submission meetings:

  • Observer
  • May ask clarification questions as needed

CDR and pCODR processes:

  • Authorized recipient of drug submission or resubmission information, including confidential or non-disclosable information, as well as non-redacted outputs from the CDR and pCODR processes

CDEC and pERC meetings:

  • Observer

DPAC-FWG:

  • Observer
  • May provide updates or contribute to potential drug recommendation implementation issues that fit within the scope of CDR reviews, therapeutic reviews, or optimal use reviews

PAC-PAG:

  • Observer
  • May provide updates or contribute to potential drug recommendation implementation issues that fit within the scope of pCODR reviews

CDR = CADTH Common Drug Review; CDEC = CADTH Canadian Drug Expert Committee; DPAC-FWG = Drug Policy Advisory Committee-Formulary Working Group; PAC-PAG = pCODR Advisory Committee-Provincial Advisory Group; pCODR = CADTH pan-Canadian Oncology Drug Review; pERC = CADTH pCODR Expert Review Committee

For more details please refer to the CDR Update — Issue 119 Published on: May 26, 2016

Now that the pCPA is receiving drug information earlier in the process, will the time required for pCPA negotiations with manufacturers be reduced?

For more information, please contact Marla Weingarten, Consultant, The Pangaea Group